Exploring biomarkers for prognosis in recurrent and metastatic colorectal cancer after surgery
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Secondary Radical Surgery by Multi-omics Methods
This study is trying to find specific markers in blood and tumor samples that can help predict how well patients with recurring or advanced colorectal cancer will do after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT05501353 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes a multi-omics approach to identify biomarkers that may predict the prognosis of patients with recurrent and metastatic colorectal cancer following secondary radical resection. The research focuses on detecting DNA mutations and methylation patterns in tumor tissues using next-generation sequencing (NGS) technology, as well as analyzing circulating tumor DNA (ctDNA) in preoperative and postoperative blood samples. By correlating these molecular markers with patient outcomes, the study aims to enhance understanding of recurrence risk and improve prognostic accuracy.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of colorectal cancer who have experienced their first recurrence and metastasis after prior radical resection.
Not a fit: Patients currently participating in other intervention studies or those with concurrent malignant tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prognostic tools for patients with recurrent and metastatic colorectal cancer, potentially guiding treatment decisions.
How similar studies have performed: While this approach is innovative, similar studies utilizing multi-omics methods have shown promise in other cancer types, suggesting potential for success in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Colorectal cancer patients with first recurrence and metastasis after previous radical resection 2. Single site/organ metastasis is indicative of reoperation 3. Adenocarcinoma diagnosed by histology or cytology 4. At the time of signing the informed consent, the applicant must be 18 years old or older 5. Life expectancy is at least 12 weeks 6. ECOG score 0\~1 Exclusion Criteria: 1. Currently participating in the intervention study treatment, or receiving other drugs or study devices within 4 weeks before enrollment 2. Concurrent with other malignant tumors 3. The investigator determined that the patient had other serious diseases that might affect follow-up and short-term survival 4. Cardiac function NYHA class III or IV heart disease 5. The presence of definite peripheral nerve disease 6. There is definite hearing loss 7. Other researchers think it is not suitable for inclusion
Where this trial is running
Hangzhou, Zhejiang
- the Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Lifeng Sun
- Email: sunlifeng@zju.edu.cn
- Phone: 13958103041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.